The diagnosis of pediatric multiple sclerosis (MS) is challenging due to its low frequency and the overlap with other acquired childhood demyelinating disorders of the central nervous system. To identify potential protein biomarkers which could facilitate the diagnosis, we used two-dimensional gel electrophoresis (2-DE) in combination with mass spectrometry to identify proteins associated with pediatric MS. Plasma samples from nine children with MS and nine healthy subjects, matched in aggregate by age and gender, were analyzed for differences in their patterns of protein expression. We found 12 proteins that were significantly up regulated in the pediatric MS group: alpha-1-acid-glycoprotein 1, alpha-1-B-glycoprotein, transthyretin, apoliprotein-C-III, serum amyloid P component, complement factor-I, clusterin, gelsolin, hemopexin, kininogen-1, hCG1993037-isoform, and vitamin D-binding protein. These results show that 2-DE in combination with mass spectrometry is a highly sensitive technique for the identification of blood-based biomarkers. This proteomic approach could lead to a new panel of diagnostic and prognostic markers in pediatric MS.
1 Boiko A Vorobeychik G Paty D Devonshire V Sadovnick D . Early onset multiple sclerosis: a longitudinal study. Neurology2002; 59: 1006–1010.
2.
2 Ness JM Chabas D Sadovnick AD Pohl D Banwell B Weinstock-Guttman B . Clinical features of children and adolescents with multiple sclerosis. Neurology2007; 68: S37–S45.
3.
3 Schwarz S Mohr A Knauth M Wildemann B Storch-Hagenlocher B . Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology2001; 56: 1313–1318.
4.
4 Banwell B Krupp L Kennedy J . Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol2007; 6: 773–781.
5.
5 Ghezzi A Pozzilli C Liguori M . Prospective study of multiple sclerosis with early onset. Mult Scler2002; 8: 115–118.
6.
6 Martin R Leppert D . A plea for "omics" research in complex diseases such as multiple sclerosis–a change of mind is needed. J Neurol Sci2004; 222: 3–5.
7.
7 Gygi SP Rochon Y Franza BR Aebersold R . Correlation between protein and mRNA abundance in yeast. Mol Cell Biol1999; 19: 1720–1730.
8.
8 Celis JE Kruhoffer M Gromova I . Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett2000; 480: 2–16.
9.
9 Lian Z Wang L Yamaga S . Genomic and proteomic analysis of the myeloid differentiation program. Blood2001; 98: 513–524.
10.
10 Oberemm A Onyon L Gundert-Remy U . How can toxicogenomics inform risk assessment. Toxicol Appl Pharmacol2005; 207: 592–598.
11.
11 Rodland KD . Proteomics and cancer diagnosis: the potential of mass spectrometry. Clin Biochem2004; 37: 579–583.
12.
12 Goldknopf IL . Blood-based proteomics for personalized medicine: examples from neurodegenerative disease. Expert Rev Proteomics2008; 5: 1–8.
13.
13 Kim JK Mastronardi FG Wood DD Lubman DM Zand R Moscarello MA . Multiple Sclerosis: an important role for post-translational modifications of MBP in pathogenesis. Mol Cell Proteomics2003; 2: 453–462.
14.
14 Krupp LB Banwell B Tenembaum S . Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology2007; 68: S7–S12.
15.
15 Rithidech KN Honikel L Simon SR . Radiation leukemogenesis: a proteomic approach. Exp Hematol2007; 35: 117–124.
16.
16 Anderson NL Polanski M Pieper R . The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics2004; 3: 311–326.
17.
17 Kermode AG Thompson AJ Tofts P . Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multipke sclerosis: pathogentic and clinical implications. Brain1990; 113: 1477–1489.
18.
18 Gygi SP Aebersold R . Mass spectrometry and proteomics. Curr Opin Chem Biol2000; 4: 489–494.
19.
19 Kinter M Sherman NE . Protein sequencing and identification using tandem mass spectrometry.New York: Wiley Interscience; 2002 [Multi Probe II HT Ex, Perkin Elmer].
20.
20 Unlu M Morgan ME Minden JS . Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis1997; 18: 2071–2077.
21.
21 Dumont D Noben JP Raus J Stinissen P Robben J . Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics2004; 4: 2117–2124.
22.
22 Hammack BN Fung KY Hunsucker SW . Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler2004; 10: 245–260.
23.
23 Lehmensiek V Sussmuth SD Tauscher G . Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler2007; 13: 840–849.
24.
24 O'Connor KC Roy SM Becker CH Hafler DA Kantor AB . Comprehensive phenotyping in multiple sclerosis: discovery based proteomics and the current understanding of putative biomarkers. Dis Markers2006; 22: 213–225.
25.
25 Agnello D Carvelli L Muzio V . Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram. J Neuroimmunol2000; 109: 105–111.
26.
26 Chrostek L Cylwik B Krawiec A Korcz W Szmitkowski M . Relationship between serum sialic acid and sialylated glycoproteins in alcoholics. Alcohol Alcohol2007; 42: 588–592.
27.
27 Harrington MG Aebersold R Martin BM Merril CR Hood L . Identification of a brain-specific human cerebrospinal fluid glycoprotein, beta-trace protein. Appl Theor Electrophor1993; 3: 229–234.
28.
28 Adam P Sobek O Taborsky L Hildebrand T Tutterova O Zacek P . CSF and serum orosomucoid ([alpha]-1-acid glycoprotein) in patients with multiple sclerosis: a comparison among particular subgroups of MS patients. Clin Chim Acta2003; 334: 107–110.
29.
29 Wong C-T Tsoi W-F Saha N . Acute phase proteins in male Chinese schizophrenic patients in Singapore. Schizophr Res1996; 22: 165–171.
30.
30 Chandler S Miller KM Clements JM . Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol1997; 72: 155–161.
31.
31 Yong VW Power C Forsyth P Edwards DR . Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci2001; 2: 502–511.
32.
32 Lee MA Palace J Stabler G Ford J Gearing A Miller K . Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis: a longitudinal clinical and MRI study. Brain1999; 122: 191–197.
33.
33 Colman RW Sartor RB Adam AA DeLa Cadena RA Stadnicki A . The plasma kallikrein-kinin system in sepsis, inflammatory arthritis, and enterocolitis. Clin Rev Allergy Immunol1998; 16: 365–384.
34.
34 Prat A Biernacki K Saroli T . Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch Neurol2005; 62: 795–800.
35.
35 Munger KL Levin LI Hollis BW Howard NS Ascherio A . Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA2006; 296: 2832–2838.
36.
36 White P Cooke N . The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab2000; 11: 320–327.
37.
37 Kim H-J DiBernardo AB Sloane JA . WAVE1 is required for oligodendrocyte morphogenesis and normal CNS myelination. J Neurosci2006; 26: 5849–5859.
